HomeCompareGNBT vs SPHD

GNBT vs SPHD: Dividend Comparison 2026

GNBT yields 333333.33% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNBT wins by $8.099219044190773e+31M in total portfolio value
10 years
GNBT
GNBT
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full GNBT calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — GNBT vs SPHD

📍 GNBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNBTSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNBT + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNBT pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNBT
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, GNBT beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNBT + SPHD for your $10,000?

GNBT: 50%SPHD: 50%
100% SPHD50/50100% GNBT
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNBT buys
0
SPHD buys
0
No recent congressional trades found for GNBT or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNBTSPHD
Forward yield333333.33%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.099219044190773e+31M$26.5K
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00$571.32
Total dividends collected$8.098906375781879e+31M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GNBT vs SPHD ($10,000, DRIP)

YearGNBT PortfolioGNBT Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$33,344,033$33,333,333.33$11,133$432.85+$33.33MGNBT
2$103,911,171,366$103,875,493,250.26$12,363$450.36+$103911.16MGNBT
3$302,644,656,190,810$302,533,471,237,448.00$13,695$467.39+$302644656.18MGNBT
4$823,817,797,451,856,400$823,493,967,669,732,100.00$15,138$483.90+$823817797451.84MGNBT
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$16,697$499.88+$2095836995961804.00MGNBT
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$18,382$515.31+$4983251920823461888.00MGNBT
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$20,198$530.17+$1.1073835968753322e+22MGNBT
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$22,157$544.46+$2.2999277308531335e+25MGNBT
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$24,266$558.18+$4.464390519999121e+28MGNBT
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$26,536$571.32+$8.099219044190773e+31MGNBT

GNBT vs SPHD: Complete Analysis 2026

GNBTStock

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

Full GNBT Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this GNBT vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNBT vs SCHDGNBT vs JEPIGNBT vs OGNBT vs KOGNBT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.